Zacks Research Issues Positive Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th. Zacks Research analyst K. Shah now anticipates that the company will earn $4.31 per share for the year, up from their previous forecast of $4.12. The consensus estimate for Sanofi’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi’s Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

Other analysts also recently issued reports about the stock. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Up 1.1 %

SNY stock opened at $48.51 on Monday. The firm’s fifty day simple moving average is $54.45 and its 200-day simple moving average is $52.22. The company has a market capitalization of $123.11 billion, a P/E ratio of 24.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.55 EPS.

Hedge Funds Weigh In On Sanofi

Several large investors have recently made changes to their positions in SNY. POM Investment Strategies LLC acquired a new position in Sanofi during the second quarter worth $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi during the third quarter worth $29,000. Concord Wealth Partners raised its position in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp acquired a new position in Sanofi during the second quarter worth $35,000. Finally, Fortitude Family Office LLC raised its position in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.